Commercial Novo hits back at rivals with cut-price Wegovy subscriptions PharmaphorumTrying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers.CommercialMetabolic & GLP-1Read full story pharminent March 31, 2026 (Last updated: April 1, 2026) Pharmaphorum Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers. CommercialMetabolic & GLP-1Read full story Post navigation Previous: Lilly beefs up neuroscience pipeline with $6.3B Centessa buyoutNext: S16 Ep43: FDA Approval Insights: Rucaparib for BRCA Mutation-Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026
